Yazar "Kazanci, Fatmanur" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Is Kidney Injury Molecule 1 a Valuable Tool for the Early Diagnosis of Contrast-Induced Nephropathy?(Bmj Publishing Group, 2015) Akdeniz, Derya; Celik, Huseyin Tugrul; Kazanci, Fatmanur; Yilmaz, Hakki; Yalcin, Serkan; Bilgic, Mukadder Ayse; Ruzgaresen, NuketAim/Scope Contrast-induced nephropathy (CIN) is a common complication of diagnostic/therapeutic procedures. Serum creatinine levels are sensitive but often lead to diagnostic delays in acute kidney injury and potential misclassification of actual injury status. Kidney injury molecule (KIM-1) is a novel early marker of acute kidney injury. The aim of our study was to evaluate the KIM-1 levels in patients with CIN. We performed a single-center, nested case-control study. Materials and Methods Three thousand two hundred patients who had undergone coronary angiography were included in the study. Thirty-two patients were diagnosed with CIN. Twenty patients who had undergone coronary angiography but did not have CIN were evaluated as a control group (n = 20). The diagnosis of CIN was performed according to the KDIGO 2012 Acute Kidney Injury Guideline criteria. Urinary KIM-1 levels were measured by enzyme-linked immunosorbent assay before as well as on the 6th and 48th hours of contrast exposure. Serum creatinine levels were measured before as well as on the 24th and 48th hours after angiographic procedure. Results We demonstrated that KIM-1 levels increased in the patients with CIN significantly on the sixth hour when compared with the baseline (P < 0.01; median levels, 0.27 and 0.70 mg/dL) but not in the controls (P = 0.107). The precontrast and 48th-hour KIM-1 levels were median ones and were also significantly different (P = 0.001, the median levels were 0.27 and 0.60 mg/dL, respectively). Conclusions Because creatinine is a sensitive but a late marker of CIN, KIM-1 may be used for early diagnosis and early initiation of treatment and may reduce risk for morbidity.Öğe Serum adropin as a predictive biomarker of erectile dysfunction in coronary artery disease patients(Polish Urological Assoc, 2019) Celik, Husetin Tugrul; Bilen, Mehmet; Kazanci, Fatmanur; Yildirim, Mehmet Erol; Incebay, Ilkay Bekir; Erdamar, HusamettinIntroduction Erectile dysfunction (ED) is associated with various comorbidities and an early diagnosis and treatment is necessary to avoid the development of these comorbidities. Unfortunately, there is no biochemical marker that can be used for early diagnosis of ED. Nitric oxide (NO) is released by nerve and endothelial cells in the corpora cavernosa of the penis and is believed to be the main vasoactive chemical mediator of penile erection. Adropin is a regulatory peptide which has effects on NO bioavailability and energy homeostasis. We hypothesized that adropin may contribute to the pathogenesis of ED because of the presence of both metabolic effects and the influence on NO bioavailability. To confirm this hypothesis, we investigated the relationship between ED and serum adropin and NO levels. Materials and Methods: Seventy-five ED patients were enrolled for this study and the patients were divided into two groups according to angiographic scoring. Serum NO and adropin levels were measured by the Griess reaction and ELISA method, respectively. Results: Serum adropin and NO levels were found to be lower in the group which has higher angiographic score and the difference in NO was statistically significant. Also, adropin has a significant correlation between IIEF scores in ED patients. Conclusion: This is the first study in the literature investigating the levels of adropin in ED patients having coronary artery disease. The adropin molecule shows a promising future in clarifying the etiopathogenesis of ED. More comprehensive and multicenter studies are needed to reveal the role of adropin in ED and the effects of treatment on this molecule.Öğe The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin(Clin Lab Publ, 2015) Celik, Huseyin Tugrul; Akkaya, Nermin; Erdamar, Husamettin; Gok, Sumeyye; Kazanci, Fatmanur; Demircelik, Bora; Cakmak, MuzafferBackground: Hypertension and obesity are two major threats for public health. Up to the present, antihypertensive medications have been used to lower blood pressure, which seem to provide a better life with lower morbidity and mortality rates. Their effect on etiopathogenesis of hypertension is now an area of developing research. The association between hypertension and obesity also suggests the link between antihypertensive agents and energy hemostasis. We aimed to investigate the effects of antihypertensive treatment on the irisin, adropin, and perilipin levels in patients with essential hypertension and to compare them with healthy volunteers in terms of their effect on energy hemostasis. Methods: In total, 85 newly diagnosed patients with untreated essential hypertension were admitted to the outpatient clinic. Patients were randomized to one of the following treatment protocols: amlodipine or valsartan for a 12 week period. 42 patients were randomized into the valsartan group and 43 patients into the amlodipine group. Serum perilipin, irisin, and adropin levels were measured before and after drug treatment by ELISA kits. Results: We discovered that the hypertensive patients have lower levels of perilipin and higher levels of adropin compared with the control group. Both amlodipine and valsartan increased the levels of perilipin, irisin, and adropin after 12 weeks of treatment. Conclusions: In conclusion, in regulating energy balance, perilipin, irisin, and adropin, could be of pathogenic importance in obesity-induced hypertension. Hence, ongoing trials need to elucidate this mechanism.Öğe The Role of Asymmetric Dimethyl Arginine and Nitric Oxide in Patients with Chronic Pancreatitis(Canadian Soc Clinical Investigation, 2015) Cakmak, Muzaffer; Erdamar, Husamettin; Kazanci, Fatmanur; Gok, Sumeyye; Abusoglu, Sedat; Unlu, Ali; Aydin, SafakPurpose: Endothelial dysfunction (ED) is a well-known pathological feature in the development of many diseases. The dysfunctional condition includes reduction in nitric oxide (NO) bioavailability. Chronic pancreatitis (CP) is a progressive and irreversible destruction of pancreas, and may lead to varying degrees of endocrine and exocrine dysfunction. NO released from endothelial cells is thought to be involved in the pathogenesis of CP; however, there is no study investigating the relationship between CP and ED. The purpose of this study was to investigate the levels of NO and methylarginines, including AMDMA, in patients with CP. Patients and Methods: A total of 44 patients with CP and 36 healthy volunteers were included in this study. Serum levels of ADMA, SDMA, NMMA, arginine, and citrulline were analyzed by LC-MS/MS and nitric oxide levels were analyzed using ELISA. Results: Serum SDMA levels were higher in patients with CP (0.55 +/- 0.02 mu mol/L vs. 0.47 +/- 0.02 mu mol/L, p=0.041), whereas NMMA levels were lower in patients with CP (0.052 +/- 0.003 mu mol/L vs 0.068 +/- 0.003 mu mol/L, p<0.001). There was a correlation between the C-reactive protein and SDMA levels (r=0.443, p=0.004). Conclusion: Elevated SDMA and reduced NMMA levels may be responsible for the increased pancreatic damage. Circulating SDMA may be a better marker of stage pancreatic detriment with respect to ADMA or NO in subjects with CP. Further research for possible associations among serum SDMA, ADMA, NO and other measures of pancreatitis may be beneficial in order to better understand the pathophysiology of CP and establish more effective treatment options.
